. Risk of bias of included studies. Risk of bias across studies assessed using the Cochrane risk of bias tool (1,2). Studies are assessed on the basis of sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting and other sources of bias. (A) Risk of bias graph, each risk of bias item presented as percentages across all included studies. (B) Risk of bias summary for each included study.
. Network geometry for secondary outcomes in the network meta-analysis. Each node indicates a strategy and the node size is proportional to the number of patients in the treatment group. Lines represent direct comparisons between two treatments and line thickness represents the number of randomized controlled trials included in each comparison, also represented by the numbers. (A) DFS (10 trials), (B) distant metastases (13 trials), (C) pCR (7 trials), (D) organ preservation (6 trials), (E) anastomotic leak (9 trials) and (F) 30-day mortality (16 trials).DFS, disease-free survival; pCR, pathological complete response rate; S, surgery alone; RT, surgery preceded by neoadjuvant radiotherapy; CRT, surgery preceded by neoadjuvant chemoradiotherapy; CT, surgery preceded by neoadjuvant chemotherapy. Figure S3 . Ranking probability and SUCRA of strategies for secondary outcomes in the network meta-analysis of neoadjuvant treatments for resectable rectal cancer. Each line represents a treatment strategy. The x-axis indicates the ranking of strategies, with '1st' representing the best. The y-axis represents the probability of each ranking. (A) DFS, (B) distant metastases, (C) pCR, (D) organ preservation, (E) anastomotic leak and (F) 30-day mortality. SUCRA, surface under the cumulative ranking curve; DFS, disease-free survival; pCR, pathological complete response rate; S, surgery alone; RT, surgery preceded by neoadjuvant radiotherapy; CRT, surgery preceded by neoadjuvant chemoradiotherapy; CT, surgery preceded by neoadjuvant chemotherapy. 
